AU2016262642A1 — Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
Assigned to Xcovery Holdings Inc · Expires 2016-12-08 · 9y expired
What this patent protects
The new pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases especially against c-Met and are useful in treating disorders related to abnonnal 5 protein kinase activities such as cancer. 8427474_1 (GHMatters) P93172.AU.1 21/11/16
USPTO Abstract
The new pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases especially against c-Met and are useful in treating disorders related to abnonnal 5 protein kinase activities such as cancer. 8427474_1 (GHMatters) P93172.AU.1 21/11/16
Drugs covered by this patent
- Xalkori (crizotinib) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.